Université de Toulouse, Cancer Research Center of Toulouse, INSERM UMR 1037, 2 Avenue Hubert Curien, 31037 Toulouse, France.
Université de Toulouse, UMR 152 PharmaDev, Université Paul Sabatier, Institut de Recherche et Développement, Faculté de Pharmacie, 35 Chemin des Maraîchers, 31062 Toulouse, France.
Int J Mol Sci. 2019 Jan 8;20(1):230. doi: 10.3390/ijms20010230.
Morniga-G, the Gal-specific black mulberry () lectin, displays high affinity for T (CD176) and Tn (CD175) antigens, frequently expressed at the cancer cell surface. The effects of Morniga-G were investigated on a Tn-positive leukemic Jurkat cell line. The lectin, used in a concentration range between 5⁻20 μg/mL, induced cell death in leukemic Jurkat cells. Microscopic and cytofluorometric analyses indicated that Jurkat cell death was essentially apoptotic, associated with an increase in the ceramide content and a depolarization of the mitochondrial transmembrane potential. This lectin-mediated cell death was inhibited by the pan caspase-inhibitor zVAD. In addition, cleavage of caspases 8, 9, and 3 was observed in Morniga-G-treated Jurkat cells whereas Jurkat cell lines that are deficient in caspase 8⁻10, caspase 9, or FADD, survived to the lectin-mediated toxicity. Furthermore, in the presence of TRAIL- or DR5-blocking mononoclonal antibodies, Jurkat cells became resistant to Morniga-G, suggesting that the lectin triggers cell death via the TRAIL/DR5 pathway. In silico computer simulations suggest that Morniga-G might facilitate both the DR5 dimerization and the building of TRAIL/DR5 complexes. Finally, upon treatment of Jurkat cells with benzyl-GalNAc, an -glycosylation inhibitor, a decrease in Tn antigen expression associating with a reduced Morniga-G toxicity, was observed. Taken together, these results suggest that Morniga-G induces the cell death of Tn-positive leukemic cells via concomitant -glycosylation-, caspase-, and TRAIL/DR5-dependent pathways.
早上好-G,一种特异性识别 Gal 的黑桑椹凝集素,对 T(CD176)和 Tn(CD175)抗原具有高亲和力,这些抗原通常在癌细胞表面表达。本研究考察了 Morniga-G 对 Tn 阳性白血病 Jurkat 细胞系的作用。该凝集素的使用浓度范围在 5⁻20 μg/mL 之间,诱导白血病 Jurkat 细胞死亡。显微镜和细胞荧光分析表明,Jurkat 细胞死亡主要是凋亡,伴随着神经酰胺含量增加和线粒体跨膜电位去极化。这种凝集素介导的细胞死亡可被广谱半胱天冬酶抑制剂 zVAD 抑制。此外,在 Morniga-G 处理的 Jurkat 细胞中观察到 caspase-8、caspase-9 和 caspase-3 的裂解,而缺乏 caspase-8-10、caspase-9 或 FADD 的 Jurkat 细胞系则对凝集素介导的毒性有抗性。此外,在 TRAIL 或 DR5 阻断单克隆抗体存在的情况下,Jurkat 细胞对 Morniga-G 产生抗性,表明该凝集素通过 TRAIL/DR5 途径触发细胞死亡。计算机模拟表明,Morniga-G 可能促进 DR5 二聚化和 TRAIL/DR5 复合物的形成。最后,用苄基-GalNAc(一种 - 糖苷酶抑制剂)处理 Jurkat 细胞后,观察到 Tn 抗原表达减少,同时 Morniga-G 毒性降低。综上所述,这些结果表明 Morniga-G 通过协同的 - 糖基化、半胱天冬酶和 TRAIL/DR5 依赖途径诱导 Tn 阳性白血病细胞死亡。